Novartis announced today that the European Commission has approved pasireotide for the treatment of adult patients with Cushing's disease for whom surgery is not an option or for whom surgery has failed.

Pasireotide is the first medicine to be approved in the European Union (EU) targeting Cushing’s disease.

The approval is based on data from the largest randomised Phase III study to evaluate a medical therapy in patients with Cushing’s disease, a disorder caused by excess cortisol in the body due to the presence of a non-cancerous pituitary tumour.

In the study, mean urinary-free cortisol (UFC) levels were normalised in 26.3% and 14.6% of the 162 patients randomised to receive Signifor 900μg and 600μg subcutaneous (sc) injection twice daily, respectively, at month six.

The primary endpoint, the proportion of patients who achieved normalization of UFC after six months without dose up-titration relative to randomised dose, was met in patients treated with 900μg twice daily.

In addition, the study showed the majority of the patients remaining on the study at month six (91 out of 103 patients; 88%) had any reduction in their mean UFC5. The median reduction in mean UFC was 47.9% in both dose groups. Reductions in UFC were rapid and sustained through the end of the study, with the majority of patients experiencing a decrease within the first two months4.

Overall reductions in the clinical manifestations of Cushing's disease, including blood pressure, total cholesterol, weight and body mass index, were observed at months six and twelve in patients with both full and partial mean UFC control, with the greatest reductions observed in patients with normalised UFC levels.

“As the first therapeutic option to specifically target Cushing’s disease, pasireotide has the potential to redefine treatment of this debilitating disease,” said Hervé Hoppenot, President, Novartis Oncology.

“By focusing research efforts on our understanding of this rare disease where there is significant unmet need, we have been able to successfully bring a novel treatment option to patients in the European Union.”

Cushing’s disease most commonly affects adults as young as 20 to 50 years and affects women three times more often than men. It may present with weight gain, central obesity, a round, red and full face, severe fatigue and weakness, striae (purple stretch marks), high blood pressure, depression and anxiety.

“Patients with Cushing’s disease often struggle with a variety of debilitating health issues associated with the overproduction of cortisol and previously were faced with a treatment approach limited to surgery,” said Ellen van Veldhuizen, board member of the Dutch Adrenal Society. “The approval of pasireotide as a new treatment option that may help patients with Cushing’s disease is welcome news.”

The decision follows the positive opinion the Committee for Medicinal Products for Human Use (CHMP) adopted for Signifor in January 2012 for the treatment of Cushing’s disease and Signifor has orphan drug designation for Cushing’s disease, a condition which affects no more than five in 10,000 people in the EU, the threshold for orphan designation.

Additional, regulatory submissions for pasireotide for the treatment of Cushing’s disease are under way worldwide.

Source: Novartis